Team:EPF-Lausanne/Our Project/TetR mutants

From 2011.igem.org

(Difference between revisions)
 
(2 intermediate revisions not shown)
Line 1: Line 1:
{{:Team:EPF-Lausanne/Templates/TetRtemplate|title=''In-Vitro'' Characterization}}
{{:Team:EPF-Lausanne/Templates/TetRtemplate|title=''In-Vitro'' Characterization}}
-
When we generate new libraries of transcription factors using site-directed mutagenesis, we need to have a precise and high-throughput characterization method. These two requirements are present in the microfluidics MITOMI device that we used.
+
When we generate new libraries of transcription factors using site-directed mutagenesis, we need to have a precise and high-throughput characterization method. These two requirements are met by the microfluidics MITOMI device that we used.
 +
Characterizing a lot of different mutants will allow us to get a better understanding of the mutations influencing the specificity and affinity of a transcription factor. With these parameters in hand, we will be able to fine-tune the characteristics of the newly produced transcription factors.
-
Characterizing a lot of different mutants will allow to get a better understanding on the the mutations influencing the specificity and affinity of a transcription factor. Once with these parameters in hand, we will be able to fine-tune the characteristics of the newly produced TFs.
+
The new transcription factors mutants characterized in vitro then need to be tested ''in vivo''. This last step is explained in the " ''in vivo'' characterization section".
-
 
+
-
 
+
-
The new transcription factors mutants characterized in vitro then need to be tested in vitro. This last step is explained in the " ''in vivo'' characterization section".
+
 +
[[File:EPFL-Solange-MITOMI.jpg|700px]]
{{:Team:EPF-Lausanne/Templates/Footer}}
{{:Team:EPF-Lausanne/Templates/Footer}}

Latest revision as of 02:59, 22 September 2011